All In Biotech

Drug Trial Radar · NCT07656727

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

A Phase 2, Randomized, Double-Blind, Dose-Range, Placebo-Controlled, 12-Week Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jun 11, 2026

Primary completion

Nov 30, 2026

Study completion Dec 2026

Sponsor

Lead sponsor
BioAge Labs, Inc.Industry
Sponsor type
Industry
First posted
Jun 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.

Conditions

  • Obesity and Cardiovascular Risk

Interventions

  • Oral BGE-102Drug

    Capsules

  • Oral Placebo Matching BGE-102Drug

    Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in hsCRP (Dose A)Time frame: Week 12
  2. Percent change in hsCRP (Dose B)Time frame: Week 12
  3. Percent change in hsCRP (Dose C)Time frame: Week 12

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Site 108

    Chandler, Arizona

  • Site 115

    Peoria, Arizona

  • Site 110

    Tucson, Arizona

  • Site 100

    Rogers, Arkansas

  • Site 109

    Maitland, Florida

  • Site 102

    Miami, Florida

  • Site 104

    Port Orange, Florida

  • Site 103

    Lexington, Kentucky

  • Site 106

    Rockville, Maryland

  • Site 113

    Kansas City, Missouri

  • Site 116

    Las Vegas, Nevada

  • Site 111

    Hartsdale, New York

  • Site 112

    Austin, Texas

  • Site 114

    Dallas, Texas

  • Site 101

    San Antonio, Texas

  • Site 117

    Sugar Land, Texas

  • Site 105

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.